title: [Pfizer urged to respond to criticism and participate in the public debate].
authors.affiliation: FoU-enhet, Jönköping. bengt.jarhult@lj.se
authors.forename: Järhult
authors.initials: J
authors.lastname: Bengt
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects; D016265:Conflict of Interest; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry; D004346:Drug Information Services; D005944:Glucosamine / Q000009:adverse effects; D006801:Humans; D040541:Marketing; D011639:Public Opinion; D012307:Risk Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; D005944:Glucosamine